Literature DB >> 26965028

A 5-year follow-up study of users of benzodiazepine: starting with diazepam versus oxazepam.

Ingunn Fride Tvete1, Trine Bjørner2, Tor Skomedal3.   

Abstract

BACKGROUND: Drug dependency may develop during long-term benzodiazepine use, indicated, for example, by dose escalation. The first benzodiazepine chosen may affect the risk of dose escalation. AIM: To detect possible differences in benzodiazepine use between new users of diazepam and oxazepam over time. DESIGN AND
SETTING: This 5-year prescription database study included 19 747 new benzodiazepine users, inhabitants of Norway, aged 30-60 years, with first redemption for diazepam or oxazepam.
METHOD: Individuals starting on diazepam versus oxazepam were analysed by logistic regression with sex, age, other drug redemptions, prescriber's specialty, household income, education level, type of work, and vocational rehabilitation support as background variables. Time to reach a daily average intake of ≥1 defined daily doses (DDD) over a 3-month period was analysed using a Cox proportional hazard regression model.
RESULTS: New users of oxazepam had a higher risk for dose escalation compared with new users of diazepam. This was true even when accounting for differences in sociodemographic status and previous drug use (hazard ratio [HR] 1.33, 95% confidence interval = 1.17 to 1.51).
CONCLUSION: Most doctors prescribed, according to recommendations, oxazepam to individuals they may have regarded as prone to and at risk of dependency. However, these individuals were at higher risk for dose escalation even when accounting for differences in sociodemographic status and previous drug use. Differences between the two user groups could be explained by different preferences for starting drug, DDD for oxazepam being possibly too low, and some unaccounted differences in illness. © British Journal of General Practice 2016.

Entities:  

Keywords:  Cox models; anxiety; benzodiazepines; diazepam; general practice; logistic models; oxazepam

Mesh:

Substances:

Year:  2016        PMID: 26965028      PMCID: PMC4809707          DOI: 10.3399/bjgp16X684385

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  10 in total

1.  Socioeconomic influences on benzodiazepine consumption in an Irish Region.

Authors:  P Quigley; C Usher; K Bennett; J Feely
Journal:  Eur Addict Res       Date:  2006       Impact factor: 3.015

Review 2.  Effectiveness of benzodiazepines: do they work or not?

Authors:  Malcolm Lader
Journal:  Expert Rev Neurother       Date:  2008-08       Impact factor: 4.618

3.  Influence of material deprivation on prescribing patterns within a deprived population.

Authors:  D Williams; C Teljeur; K Bennett; A Kelly; J Feely
Journal:  Eur J Clin Pharmacol       Date:  2003-08-27       Impact factor: 2.953

Review 4.  Benzodiazepines revisited--will we ever learn?

Authors:  Malcolm Lader
Journal:  Addiction       Date:  2011-10-17       Impact factor: 6.526

Review 5.  Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse.

Authors:  R R Griffiths; E M Weerts
Journal:  Psychopharmacology (Berl)       Date:  1997-11       Impact factor: 4.530

6.  Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects.

Authors:  R R Griffiths; D R McLeod; G E Bigelow; I A Liebson; J D Roache
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Comparison of diazepam and oxazepam: preference, liking and extent of abuse.

Authors:  R R Griffiths; D R McLeod; G E Bigelow; I A Liebson; J D Roache; P Nowowieski
Journal:  J Pharmacol Exp Ther       Date:  1984-05       Impact factor: 4.030

8.  Cognitive effects of long-term benzodiazepine use: a meta-analysis.

Authors:  Melinda J Barker; Kenneth M Greenwood; Martin Jackson; Simon F Crowe
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway.

Authors:  Ingunn Fride Tvete; Trine Bjørner; Tor Skomedal
Journal:  Scand J Prim Health Care       Date:  2015       Impact factor: 2.581

10.  A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing.

Authors:  Ingunn Fride Tvete; Trine Bjørner; Ivar Andreas Aursnes; Tor Skomedal
Journal:  BMJ Open       Date:  2013-10-04       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.